Holen Sie sich die Stockscreener-App
10.78
2.71%
-0.30
Handel nachbörslich:
10.60
-0.18
-1.67%
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
META_TITLE_QUOTE - Yahoo Finance
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn
Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn
Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat
Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Why Is Ocular Therapeutix Stock Gaining Monday? - Sahm
OCUL Looks 134.8% Overvalued on GF Value™ - GuruFocus
OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA - StocksToTrade
OCUL Stock Climbs As FDA Path And Cash Runway De‑Risk Story - timothysykes.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap UpShould You Buy? - MarketBeat
Why is Ocular Therapeutix stock rallying today? By Investing.com - Investing.com Canada
OCUL Looks 141.9% Overvalued on GF Value™ - GuruFocus
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com - Investing.com South Africa
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles - Investing.com
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - Stocktwits
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
(OCUL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued? - Sahm
OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210 - TradingKey
Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research - MarketBeat
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL - MarketBeat
The debate of durability in nAMD - Endpoints News
Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Ocular Therapeutix (OCUL) Holds Steady Near $9.24 as Key Resistance Looms at $9.70Institutional Buy Signals - vinanet.vn
Does Ocular Therapeutix (OCUL) Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy? - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Ocular Therapeutix Options for New Hires Carry $8.40 Price - Stock Titan
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results - simplywall.st
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says - marketscreener.com
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a 222% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights - VisionMonday.com
Sticking With This Ocular Therapeutix Price Target as Key Treatment Moves Forward - TheStreet Pro
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocular Therapeutix Inc earnings beat by $0.03, revenue topped estimates - Investing.com
Ocular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash - TradingView
Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026 - Yahoo Finance
Ocular Therapeutix 2026: Revenue $13.48M, EPS ($0.35) — 10-Q Summary - TradingView
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q2 Revenue $13.5M, vs. FactSet Est of $13.2M - marketscreener.com
OCULAR THERAPEUTIX, INC Quarterly Earnings Report - Stock Titan
Ocular Therapeutix's Q2 Net Loss Widens, Revenue Flat - finance.yahoo.com
Ocular Therapeutix Reports Q2 2026 Results, Confirms Q4 2026 AXPAXLI NDA Submission Plan for Wet AMD - Quiver Quantitative
Defilade Capital Management L.P. Purchases 805,982 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix Inc (OCUL) Institutional Confidence - TradingKey
Ocular Therapeutix, Inc. Revenue Breakdown – NASDAQ:OCUL - TradingView
BlackRock, Inc. (NASDAQ: OCUL) discloses 7.0% beneficial stake in Ocular Therapeutix - Stock Titan
Readystate Asset Management LP Makes New Investment in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix, Inc. (OCUL): Investor Outlook Reveals a 213.55% Potential Upside in Biotech Stock - DirectorsTalk Interviews
Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers - Yahoo Finance
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OCUL|Ocular Therapeutix Inc|Price:8.505|Chg%:-0.115 - TradingKey
Ocular Therapeutix (OCUL) Gains Ground: Price Action and Key Levels to WatchCommon Gap - vinanet.vn
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):